With an aging population and rising prevalence of chronic diseases, the demand for quality drugs and therapies continues to grow. The biotech industry is well-positioned to capitalize on these opportunities thanks to its robust pipeline of drugs, the use of advanced technologies in drug discovery, and rising healthcare spending.
Although BioMarin Pharmaceutical Inc. (BMRN) possesses solid growth prospects, fundamentally strong biotech majors Amgen Inc. (AMGN), Jazz Pharmaceuticals plc (JAZZ), and Vertex Pharmaceuticals Incorporated (VRTX) look even better positioned than BMRN to capitalize on the industry’s tailwinds. Therefore, it could be wise to buy these stocks.
